Dimerix Limited announces over-recruitment milestone in ACTION3 Phase 3 trial of DMX-200
Posted: 17 March 2026 Dimerix Limited has announced that the ACTION3 Phase 3 clinical trial of DMX-200 has achieved a key milestone, with the final adult patient having been dosed and total enrolment exceeding the original target. A…
MTPConnect announces 2026 Pathway to Market Medtech program cohort
Posted: 17 March 2026 MTPConnect has announced the seven Victorian medtech companies selected to participate in the 2026 Pathway to Market – Medtech Capability Uplift Program, an initiative designed to strengthen the readiness of Australian medical technology innovators…
Telix announces ProstACT Global Phase 3 Study achieves primary objectives
Posted: 17 March 2026 Telix Pharmaceuticals Limited has announced that Part 1 of the ProstACT Global Phase 3 clinical trial has achieved its primary objectives, with the company reporting an acceptable safety and tolerability profile for its investigational…
Monash University awarded up to $22.4 million funding to develop medicines for restoring lymphatic pumping
Posted: 17 March 2026 Monash University researchers have been awarded up to $22.4 million AUD from the Advanced Research Projects Agency for Health (ARPA-H) to develop new medicines aimed at restoring lymphatic vessel pumping and transport function. The…
Thermo Fisher Scientific expands presence in Ireland with new Distribution Centre
Posted: 17 March 2026 Thermo Fisher Scientific Inc has opened a new 70,000 sq.ft. distribution centre in Bracetown, County Meath, Ireland, significantly expanding the company’s infrastructure within one of the world’s leading hubs for pharmaceutical and biopharmaceutical manufacturing.…
BioMelbourne Network welcomes leadership transition and new Board appointments to support continued growth
Posted: 5 March 2026 Effective March 2026, BioMelbourne Network appoints a new Chair and welcomes new Directors to its Board, strengthening governance and strategic leadership as Victoria’s peak body in the health technologies sector. Professor Vera Ignjatovic AM, Honorary Professor in the Department of…
Stephens Lawyers & Consultants releases updated guidance on Directors’ and Officers’ liability under the Therapeutic Goods Act
Posted: 3 March 2026 Stephens Lawyers & Consultants has released updated guidance outlining the personal liability risks faced by directors and officers involved in the importation, marketing, advertising and supply of therapeutic goods in Australia. The update has…
La Trobe University signs Memorandum of Understanding with The GAIN to strengthen Australia – India innovation corridor
Posted: 2 March 2026 La Trobe University has signed a Memorandum of Understanding with The GAIN, the global accelerator arm of StartupXseed Ventures, to advance DeepTech commercialisation between Australia and India. The partnership establishes a two-way, venture-backed bridge…
Burnet Institute and WEHI unveil immune blueprint for next‐generation malaria vaccines
Posted: 2 March 2026 New research co-led by Burnet Institute and WEHI has uncovered how the human immune system fights Plasmodium vivax, paving the way for the first effective vaccine against the most widespread form of malaria.…
Peter MacCallum Cancer Centre treats first patient in Phase I trial of new CAR T-Cell Therapy
Posted: 2 March 2026 Peter MacCallum Cancer Centre has treated the milestone first patient in a first-in-human Phase I clinical trial assessing PMCC-COE19, an experimental CAR T-cell therapy fully developed by Peter Mac and manufactured onsite by Cell…
MTPConnect opens new funding round to accelerate innovation in heart disease and diabetes
Posted: 2 March 2026 MTPConnect has opened expressions of interest for a new funding round for medical devices under its Targeted Translation Research Accelerator (TTRA) initiative, with the opportunity having been supported by the Medical Research Future Fund.…
Amplia initiates new US sites for AMPLICITY Trial in advanced pancreatic cancer
Posted: 17 February 2026 Amplia has announced that two sites in the US have been initiated and will shortly be commencing recruitment activities for the AMPLICITY trial. The two sites – University of California, Irvine and The Cleveland…
